06.01.2021
Stay up to date with the latest Mycovia news, press releases, and more. If you have any questions or comments regarding media inquiries, please reach out to mediarelations@mycovia.com.
01.06.2021
Mycovia Pharmaceuticals, Inc. Announces Positive Topline Results from its Third Phase 3 Clinical Trial (ultraVIOLET) of Oteseconazole for the Treatment of Recurrent Vulvovaginal Candidiasis
12.09.2020
Mycovia Pharmaceuticals, Inc. Announces Positive Topline Results from Phase 3 VIOLET Studies of Oteseconazole in Patients with Recurrent Vulvovaginal Candidiasis
12.02.2020
Mycovia Pharmaceuticals, Inc. Announces Last Patient Completes Final Visit in their Phase 3 “ultraVIOLET Study” for Oteseconazole (VT-1161) for the Treatment of Recurrent Vulvovaginal Candidiasis (RVVC)
11.02.2020